Data for the this analysis was compiled using the DealForma database; specifically the companies and venture funding sections. We used company location data tagged with the three major U.S. biotech hubs along with primary therapeutic and technology focus areas. All data are based on publicly disclosed figures. We invite you to answer interesting questions using our data and carefully curated profiles on deals, pipelines, companies, funding, and business executives by visiting dealforma.com to schedule your personalized demo.
Global biotechnology venture investment topped $11.8 billion in 258 financing rounds in the first 10 months of 2018. Who are the top biotech venture investors, where are they investing their money, and what are they investing in? We used DealForma’s extensive database and research capabilities to gather publicly disclosed data from January 1, 2015 through October 31, 2018 and answer these questions. In all, we looked at 1,027 venture rounds at 824 companies with 1,193 investors. The financials in this report are for the round, not that investor’s share.
No matter how you slice it, by number of investments or total dollar value of each investment, a small handful of firms top the list:
These figures are available for download below.
Update: Check out how Celgene ranked among cancer investments in an updated table for 2010 to 2018 here
Although it is impossible to know the actual size of these firms’ investments, many times these VCs are the lead investor in a financing. Notable financings in 2018 where they were the lead investor include:
Venture investors tend to take an active role in the companies in which they invest and as such often invest in companies near them so they don’t have to travel as much. Of the twelve most active firms in terms of number of investments and size of rounds over the past four years, five have headquarters or a presence in the Boston/Cambridge, Massachusetts area, while six have a presence in the San Francisco Bay Area. Many have more than one location, including ARCH Ventures—headquartered in Chicago but with offices in San Francisco, Boston, Seattle, Austin, and Dublin, Ireland; New Enterprise Associates—headquartered in Chevy Chase, Maryland but with offices in Menlo Park, CA; and OrbiMed Advisors—headquartered in New York City, but with an office in San Francisco and major countries around the world.
Thus many of their dollars go to companies located in the Boston/Cambridge and San Francisco Bay Area hubs. The data shows that Cormorant has invested solely in biotechs in the Boston/Cambridge hub, while San Diego’s share of deals and dollars has been growing, especially from local investors, such as Avalon Ventures, Illumina, Biomed Realty Ventures, Qualcomm, and Viking Therapeutics:
Want data for your analysis? Want us to do it? Subscribers get both.
Schedule your demo of the DealForma database to see how we help you get better reports done faster.
Specifically for Biotech, Pharma, Device, and Diagnostics
It’s no surprise that cancer continues to be the main therapeutic area of focus both for the number and size of the deals. There’s also renewed interest in therapies targeting neurologic disorders and infectious diseases:
Finally, what technologies are hot? Over the past four years, VC investment in companies developing first-in-class and best-in-class small molecule therapeutics far surpasses investment in immunotherapies, cell therapies, and gene therapies:
Next week, I’ll start a series on partnering and M&A trends as we lead up to the 2019 J.P. Morgan Healthcare Conference.
Marie Daghlian is a freelance writer and editor who reports on the business of biotechnology and healthcare technologies. She also covers the industry for Big4Bio, a daily newsletter focused on the four major biotech centers in the United States.
More from the DealForma Blog
We looked at 10 years of gene therapy deals, M&A, venture funding, and academic partnerships for an article by John Carroll at Endpoints News.
Biotech reverse mergers have been an alternate way for private biotechnology companies to gain a public listing. Here’s a quick table of over 10 years of deals.
2019 biopharma dealmaking started with a bang as the first quarter saw global biotech and pharma partnering deal values hit $38 billion in 282 deals.
Celgene was among the top investors in cancer biotech companies. This is a look at the top 10 since 2010.
Life Sciences M&A started with a bang in 2019 with one of the biggest deals to date – Bristol-Myers Squibb will acquire Celgene for $74 billion. We mined DealForma’s extensive database for historical M&A trends in biopharma, medical devices, and diagnostics to get an idea of what might lie ahead in 2019.
Innovative biotech companies are in a stronger position today as far as the value of their assets. We look at oncology deal payments by stage at signing.
Location, Location, Location: Real estate costs a lot in the three largest biotech hubs, but it’s a charm for raising capital. Biotech companies raised $37.4 billion globally in 1027 rounds of venture financing over the past four years from 2015 through the third quarter of 2018 and companies located in the San Francisco Bay Area, greater Boston area, and San Diego County accounted for 55 percent of the total raised and 46 percent of the financing activity.
Pharma deal upfront cash payments made for development and commercialization with biotech, device, diagnostics, and technology platform companies.
You met at BIO. Now it's Deal Time.
With thousands of company profiles and a decade of deals specifically in biotech and pharma, you'll take the guesswork out of deal comps. Schedule your customized demo to see how DealForma helps you win that term sheet with better data.
DealForma is the biopharma database providing you comprehensive information and analyst support hours to help you be more confident using quality data in your business development research.
Analysis / Blog